Literature DB >> 2984235

Morphine inhibits the pituitary-adrenal response to ovine corticotropin-releasing hormone in normal subjects.

R S Rittmaster, G B Cutler, D O Sobel, D S Goldstein, M C Koppelman, D L Loriaux, G P Chrousos.   

Abstract

To determine the locus of opiate modulation of ACTH secretion, 11 normal subjects were given ovine corticotropin-releasing hormone (CRH) 30 min after receiving either placebo or morphine sulfate. Plasma ACTH, cortisol, arginine vasopressin (AVP), epinephrine, norepinephrine, and CRH were measured 30 min before and up to 150 min after CRH administration. Morphine blunted the ACTH response for the first 60 min and cortisol response for the first 90 min after CRH administration. Morphine did not lower arginine vasopressin or catecholamine levels. To determine whether morphine's effect on ACTH and cortisol was due to a direct action on the corticotroph cell, dispersed rat pituitary cells were perifused with medium containing 1 microgram/ml morphine sulfate or medium alone. Morphine had no effect on the ACTH response of these cells to 10 nM CRH pulses. Similarly, morphine had no effect on ACTH production by dispersed rat pituitary cells in monolayer culture in response to 90- and 180-min incubations with 5 nM CRH. We conclude that morphine blunts the early response of the pituitary gland to CRH in vivo. Based on the lack of a direct effect of morphine on rat pituitary cells in vitro, we postulate that morphine given in vivo may modulate the pituitary ACTH response to CRH through other suprapituitary factors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2984235     DOI: 10.1210/jcem-60-5-891

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  18 in total

1.  Stimulation of the hypothalamic-pituitary-adrenal axis with the opioid antagonist nalmefene.

Authors:  Eliza B Geer; Rita E Landman; Sharon L Wardlaw; Irene M Conwell; Pamela U Freda
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

Review 2.  Drugs and HPA axis.

Authors:  Alberto Giacinto Ambrogio; Francesca Pecori Giraldi; Francesco Cavagnini
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

3.  Opioid and benzodiazepine contributions to etomidate-associated adrenal insufficiency.

Authors:  Harry Daniell
Journal:  Intensive Care Med       Date:  2008-09-16       Impact factor: 17.440

4.  Serum cortisol secretion during heroin abstinence is elevated only nocturnally.

Authors:  Su-xia Li; Jing Li; David H Epstein; Xiang Yang Zhang; Thomas R Kosten; Lin Lu
Journal:  Am J Drug Alcohol Abuse       Date:  2008       Impact factor: 3.829

Review 5.  Opioid-Induced Androgen Deficiency (OPIAD): Diagnosis, Management, and Literature Review.

Authors:  Timothy K O'Rourke; Matthew S Wosnitzer
Journal:  Curr Urol Rep       Date:  2016-10       Impact factor: 3.092

6.  Involvement of central histamine receptors in corticosterone secretion induced by intraventricular administration of morphine.

Authors:  B Cetera; J Bugajski; A Gadek-Michalska
Journal:  Agents Actions       Date:  1988-04

Review 7.  The effects of opioids and opioid analogs on animal and human endocrine systems.

Authors:  Cassidy Vuong; Stan H M Van Uum; Laura E O'Dell; Kabirullah Lutfy; Theodore C Friedman
Journal:  Endocr Rev       Date:  2009-11-10       Impact factor: 19.871

8.  Self-administration of fentanyl, cocaine and ketamine: effects on the pituitary-adrenal axis in rhesus monkeys.

Authors:  Jillian H Broadbear; Gail Winger; James H Woods
Journal:  Psychopharmacology (Berl)       Date:  2004-04-28       Impact factor: 4.530

Review 9.  Perioperative glucocorticoid coverage. A reassessment 42 years after emergence of a problem.

Authors:  M Salem; R E Tainsh; J Bromberg; D L Loriaux; B Chernow
Journal:  Ann Surg       Date:  1994-04       Impact factor: 12.969

10.  Comparison between the suppressive effects of dexamethasone and loperamide on cortisol and ACTH secretion in some pathological conditions.

Authors:  G P Bernini; G F Argenio; F Cerri; F Franchi
Journal:  J Endocrinol Invest       Date:  1994-11       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.